Grassley Releases Report Alleging Mylan Overcharged Medicaid $1.3 Billion For Epi-Pen
The analysis by the inspector general's office at the Department of Health and Human Services "should worry every taxpayer," the Iowa senator said.
Reuters:
Mylan May Have Overcharged U.S. For EpiPen By $1.27 Billion: HHS
The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday. The amount is nearly three times a proposed settlement that the company announced in October. (Erman, 5/31)
The Wall Street Journal:
Medicaid Was Overcharged $1.3 Billion For Mylan’s EpiPen, Watchdog Says
Mylan said in October it had agreed to pay $465 million to resolve the allegations by the Justice Department that the company wrongly classified the EpiPen as a generic product and thereby didn’t have to provide as much of a rebate to Medicaid as it would have for a branded drug. The Department of Health and Human Services, however, said in January that it “has not agreed to any settlement.” HHS’s watchdog, the Office of Inspector General, said in a letter to the Senate Judiciary Committee on Wednesday that it estimated Mylan owes the much larger sum. (Rockoff, 5/31)
Bloomberg:
Mylan May Have Overcharged Taxpayers By $1.27 Billion For EpiPen
Senator Charles Grassley, an Iowa Republican, on Wednesday posted a copy of a report by the Department of Health and Human Services’ Office of the Inspector General. The report says that Mylan, by classifying EpiPen as a generic drug rather than a brand-name product, shortchanged the Medicaid program for the poor. (Koons, 5/31)